老年非酒精性脂肪性肝病合并2型糖尿病患者血清TyG、内脏/皮下脂肪面积比和心脏代谢指数变化及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2024.05.013

摘要/Abstract

摘要： 目的探讨老年非酒精性脂肪性肝病(NAFLD)合并2型糖尿病(T2DM)患者血清三酰甘油葡萄糖乘积指数(TyG)、内脏/皮下脂肪面积比(VSR)和心脏代谢指数(CMI)变化及其临床意义。方法 2021年1月～2022年12月我院诊治的老年NAFLD合并T2DM患者98例和老年NAFLD患者98例,常规检测空腹三酰甘油和空腹血糖,计算TyG指数。使用内脏脂肪检测装置测量内脏脂肪面积(VFA)和皮下脂肪面积(SFA),计算VSR。常规检测腰高比(WHR),计算CMI。采用多因素Logistic回归分析影响合并T2DM的危险因素。结果 NAFLD合并T2DM组空腹血糖(FBG)、糖化血红蛋白(HbA1C)、胰岛素抵抗指数(HOMA-IR)和血清TG水平分别为(9.3±0.7)mmol/L、(9.1±1.6)%、(5.7±0.8)和(3.7±0.5)mmol/L,均显著高于NAFLD组【分别为(5.8±0.5)mmol/L、(6.1±1.2)%、(3.9±0.4)和(1.9±0.3)mmol/L,P<0.05】,而HDL-C为(1.2±0.2)mmol/L,显著低于NAFLD组【(1.5±0.4)mmol/L,P<0.05】;TyG、VSR和CMI分别为(10.8±1.5)%、(0.9±0.2)%和(1.2±0.3)%,显著高于NAFLD组【(8.7±0.4)%、(0.3±0.1)%和(0.6±0.2)%,P＜0.05】;多因素Logistic回归分析显示,TyG(OR=3.124,95%CI: 1.101～8.862)、VSR(OR=2.601,95%CI: 1.035～6.535)和CMI(OR=2.832,95%CI: 1.061～7.561)升高均为影响老年NAFLD合并T2DM的独立危险因素(P＜0.05);37例重度NAFLD合并T2DM患者TyG、VSR和CMI分别为(12.4±1.9)%、(1.2±0.3)%和(1.7±0.4)%,均显著高于61例轻中度NAFLD患者【分别为(9.7±0.6)%、(0.7±0.1)%和(0.9±0.2)%,P＜0.05】。结论在老年NAFLD患者,检测并计算TyG、VSR和CMI可帮助筛查T2DM,值得深入研究。

关键词: 非酒精性脂肪性肝病, 2型糖尿病, 三酰甘油葡萄糖乘积指数, 内脏/皮下脂肪面积比, 心脏代谢指数

Abstract: Objective The aim of this study was to explore the clinical implication of serum triglyceride-glucose index (TyG), visceral/subcutaneous fat area ratio (VSR) and cardiac metabolic index (CMI) in elderly patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM). Methods A total of 98 elderly patients with NAFLD and concomitant T2DM and another 98 elderly patients with NAFLD were enrolled in our hospital between January 2021 and December 2022, and routine biochemical parameters were determined for calculation of TyG and CMI. The VSR was obtained from calculation of body fat detected by special apparatus. The multivariate Logistic regression analysis was applied for risk factor finding. Results The fasting blood glucose, glycosylated hemoglobin, the HOMA-IR and serum triglyceride level in NAFLD patients with T2DM were(9.3±0.7)mmol/L, (9.1±1.6)%, (5.7±0.8) and (3.7±0.5)mmol/L, all significantly higher than [(5.8±0.5)mmol/L, (6.1±1.2)%, (3.9±0.4) and (1.9±0.3)mmol/L, respectively, P<0.05], while serum high-density lipoprotein cholesterol level was (1.2±0.2)mmol/L, significantly lower than [(1.5±0.4)mmol/L, P<0.05] in patients with NAFLD; the TyG, VSR and CMI were (10.8±1.5)%, (0.9±0.2)% and (1.2±0.3)%, all much higher than [(8.7±0.4)%, (0.3±0.1)% and (0.6±0.2)%, respectively, P＜0.05] in patients with NAFLD; the multivariate Logistic regression analysis showed that the TyG(OR=3.124, 95%CI:1.101-8.862), the VSR(OR=2.601, 95%CI:1.035-6.535) and CMI(OR=2.832,95%CI: 1.061-7.561) elevation were all the independent risk factors for T2DM in elderly patients with NAFLD (P＜0.05); the TyG, VSR and CMI in 37 patients with severe NAFLD and concomitant 2DM were (12.4±1.9)%, (1.2±0.3)% and (1.7±0.4)%, all much higher than [(9.7±0.6)%,(0.7±0.1)% and (0.9±0.2)%, respectively, P＜0.05] in 61 patients with mild to moderate NAFLD and T2DM. Conclusion The detection and calculation of relatively simple TyG, VSR and CMI might be help for screening T2DM in elderly patients with NAFLD, and needs further investigation.

Key words: Non-alcoholic fatty liver diseases, Type 2 diabetes mellitus, Triglyceride-glucose index, Visceral/subcutaneous fat area ratio, Cardiac metabolic index

李艳敏, 张维, 胡彦彦, 齐蕾. 老年非酒精性脂肪性肝病合并2型糖尿病患者血清TyG、内脏/皮下脂肪面积比和心脏代谢指数变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(5): 697-700.

Li Yanmin, Zhang Wei, Hu Yanyan, et al. Clinical implication of serum TyG, visceral/subcutaneous fat area ratio and cardiac metabolic index in elderly patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus[J]. Journal of Practical Hepatology, 2024, 27(5): 697-700.

参考文献

[1] Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020,158(7):1851-1864.
[2] 倪文婧,李婕,南月敏.非酒精性脂肪性肝病合并糖尿病的综合管理:2024年美国糖尿病学会指南解读.中华肝脏病杂志,2024,32(6):504-507.
[3] Tanase DM, Gosav EM, Costea CF,et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res, 2020,31(20):3920-3921.
[4] Tao LC, Xu JN, Wang TT,et al. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol, 2022,21(1):68-69.
[5] Seetharaman J, Srivastava A, Yadav RR, et al. Visceral fat indices: do they help differentiateCrohn's disease and intestinal tuberculosis in children? J Crohns Colitis, 2023,30(9):109-110.
[6] Brenes-Martín F, Melero-Jiménez V, Lopez-Guerrero MA, et al. First trimester evaluation of maternal visceral fat and its relationship with adverse pregnancy outcomes. Biology (Basel). 2023,12(2):144-145.
[7] Morys F, Dadar M, Dagher A. Association between midlife obesity and its metabolic consequences, cerebrovascular disease, and cognitive decline. J Clin Endocrinol Metab, 2021,106(10):4260-4274.
[8] Hiruma S, Shigiyama F, Hisatake S, et al. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Cardiovasc Diabetol, 2021,20(1):32-33.
[9] 中国研究型医院学会肝病专业委员会,中国医师协会脂肪性肝病专家委员会,中华医学会肝病学分会脂肪肝与酒精性肝病学组,等.中国脂肪性肝病诊疗规范化的专家建议(2019年修订版).中华肝脏病杂志, 2019, 27(10):748-753.
[10] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版).中华糖尿病杂志, 2021, 13(4):315-409.
[11] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186.
[12] Lee CH, Lui DT, Lam KS. Non-alcoholic fatty liver disease and type 2 diabetes: an update. J Diabetes Investig, 2022,13(6):930-940.
[13] Yan J, Yao B, Kuang H,et al. Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology, 2019,69(6):2414-2426.
[14] Isaacs S. Nonalcoholic fatty liver disease. Endocrinol Metab Clin North Am, 2023,52(1):149-164.
[15] 赵玲玲,王贝贝,姚勇利,等.T2DM合并非酒精性脂肪性肝病伴进展性肝纤维化患者血清抵抗素和TyG指数变化及其临床意义探讨.实用肝脏病杂志, 2023, 26(3):356-359.
[16] Ramdas Nayak VK, Satheesh P. Triglyceride glucose (TyG) index: a surrogate biomarker of insulin resistance. J Pak Med Assoc,2022,72(5):986-988.
[17] Saiki A, Yamaguchi T, Sasaki A, et al. Background characteristics and diabetes remission after laparoscopic sleeve gastrectomy in Japanese patients with type 2 diabetes stratified by BMI: subgroup analysis of J-SMART. Diabetol Int, 2021,12(3):303-312.
[18] Yan J, Yao B, Kuang H,et al. Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology, 2019,69(6):2414-2426.
[19] Alizargar J, Bai CH, Hsieh NC,et al. Use of the triglyceride-glucose index (TyG) in cardiovascular disease patients. Cardiovasc Diabetol, 2020,19(1):8-9.
[20] 刘奕婷,王巍,佟静,等.甘油三酯葡萄糖指数与非酒精性脂肪性肝病的关联性研究.中华肝脏病杂志, 2021, 29(5):451-455.

老年非酒精性脂肪性肝病合并2型糖尿病患者血清TyG、内脏/皮下脂肪面积比和心脏代谢指数变化及其临床意义探讨^*

Clinical implication of serum TyG, visceral/subcutaneous fat area ratio and cardiac metabolic index in elderly patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	贾双珍, 吴天威, 吴捷. microRNA-122与非酒精性脂肪性肝病研究进展^*[J]. 实用肝脏病杂志, 2024, 27(5): 646-649.
[2]	中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27(4): 494-510.
[3]	李开楊, 赵琦, 黄敬, 唐云, 蔺晓源, 刘杰民, 杨梅. 中国临床试验注册中心注册的非酒精性脂肪性肝病临床试验特征分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 531-534.
[4]	农晓黎, 陈菲, 詹浩洪, 罗婷, 曾碧丹. 体检人群非酒精性脂肪性肝病发病率及其相关危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 353-356.
[5]	孙世磊, 刘翠翠, 李曙光, 鲁科翔. 非酒精性脂肪性肝病合并T2DM患者血清成纤维细胞生长因子-21和分泌型卷曲相关蛋白5水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(3): 357-360.
[6]	高洋, 张静, 卢宣霖. 非酒精性脂肪性肝病患者血清IL-1RA、CTRP13和CK-18水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(2): 185-188.
[7]	郭萌, 郭琦, 张峰. 超声瞬时弹性成像检测受控衰减参数评估非酒精性脂肪性肝病患者肝脂肪变程度价值研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 189-192.
[8]	李敏, 张丽, 曾艾, 刘世裕. 2型糖尿病合并非酒精性脂肪性肝病患者肝纤维化检出率及预测因素分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 193-197.
[9]	郑波, 哈丽达·夏尔甫哈孜, 谈理. 非酒精性脂肪性肝病患者血清HIF-1α、HMGB1和脂联素水平变化及其与颈动脉粥样硬化的关系研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 198-201.
[10]	黄洁杰, 郑倩, 吕睿, 王瑞萍. 利拉鲁肽联合阿托伐他汀钙治疗伴有糖脂代谢异常的非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 36-39.
[11]	王文川, 梁阔鹏, 何蕊玲, 王继涛, 吉晓林, 刘成禹, 张宣哲, 张清格, 郭海军, 张健, 高华方, 郑少阳, 祁小龙, 刘登湘. 社区2型糖尿病合并NAFLD患病流行率调查^*[J]. 实用肝脏病杂志, 2024, 27(1): 40-43.
[12]	蔺宁, 孔明, 段钟平. 非酒精性脂肪性肝病营养干预研究进展^*[J]. 实用肝脏病杂志, 2024, 27(1): 151-154.
[13]	曾静, 范建高. 代谢相关脂肪性肝病自然史研究进展[J]. 实用肝脏病杂志, 2023, 26(6): 769-772.
[14]	周季颖, 谢月红, 于翠霞. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 793-796.
[15]	卢蓉, 李慧, 张超, 邵正健, 罗大光. 甘油三酯/葡萄糖指数预测非酒精性脂肪性肝病严重程度效能研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 805-810.